JNJHealthcare · Drug Manufacturers - GeneralThe 23 Wall Street analysts covering Johnson & Johnson hold a median 12-month price target of $284 — +11.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Johnson & Johnson on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JNJ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.3% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | JP Morgan | Maintains | Neutral | $270 → $285 |
| 10 Sept 2026 | HSBC | Maintains | Buy | — |
| 10 Sept 2026 | HSBC | Maintains | Buy | $290 → $320 |
| 2 Sept 2026 | UBS | Maintains | Buy | $280 → $320 |
| 2 Sept 2026 | UBS | Maintains | Buy | — |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $270 → $287 |
| 3 Aug 2026 | Wells Fargo | Maintains | Overweight | $272 → $282 |
| 3 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 17 July 2026 | Guggenheim | Reiterates | Buy | — |
| 17 July 2026 | Guggenheim | Reiterates | Buy | $270 |
| 16 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 16 July 2026 | Morgan Stanley | Maintains | Overweight | $284 → $294 |
| 16 July 2026 | Raymond James | Maintains | Outperform | $258 → $265 |
| 16 July 2026 | Raymond James | Maintains | Outperform | — |
| 16 July 2026 | RBC Capital | Reiterates | Outperform | — |
| 16 July 2026 | RBC Capital | Reiterates | Outperform | $287 |
| 16 July 2026 | Wells Fargo | Maintains | Overweight | $263 → $272 |
| 16 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 July 2026 | RBC Capital | Maintains | Outperform | $265 → $287 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JNJ appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Johnson & Johnson returned +38.4% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 20% of US stocks
Cheaper than 13% of US stocks
Cheaper than 17% of US stocks
Higher than 43% of US stocks
Higher than 36% of US stocks
Higher than 81% of US stocks
Higher than 87% of US stocks
Higher than 83% of US stocks
Higher than 85% of US stocks
Higher than 90% of US stocks
Higher than 79% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Johnson & Johnson has a market value of $617.0B and an enterprise value of $645.3B.
Revenue in the twelve months to 30 June 2026: $97.9B. The latest quarter grew 6.6% year on year.
Net income over the same four quarters: $21.0B, a 21.5% net margin.
Diluted earnings per share, trailing twelve months: $8.63.
Free cash flow in the twelve months to 30 June 2026: $22.2B, after $5.4B of capital spending.
Johnson & Johnson spent $8.1B on share buybacks and $12.6B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 29.7×; forward P/E: 21.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.09%, paying out 61% of earnings.
Johnson & Johnson employs 138,200 people — $709K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Johnson & Johnson — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A report asks whether J&J’s MedTech business can rebound in Q3 after a Q2 slowdown, noting Abiomed and competitive pressures alongside potential contributions from Vision, Orthopedics and Surgery.
Why it matters — The outlook for these MedTech areas could shape expectations for J&J’s performance in the second half.
Zacks Investment Research frames a comparison of Pfizer and Johnson & Johnson, asking which stock offers value investors better value. The excerpt does not provide a conclusion.
Why it matters — JNJ watchers may be interested in how the company is being compared with Pfizer from a value-investing perspective.
The article highlights Procter & Gamble’s 70-year record of dividend increases and names four other stocks as sharing its reliability. It cautions that dividend yield alone does not show whether a payout can withstand a recession or patent cliff.
Why it matters — A JNJ watcher may find the article’s focus on dividend durability relevant when assessing JNJ’s dividend, though the supplied excerpt does not identify JNJ among the four stocks.
Zacks Investment Research says Johnson & Johnson lacks the combination of two key ingredients associated with a likely earnings beat in its upcoming report. The item says it outlines key expectations for the report.
Why it matters — JNJ watchers may note the article’s assessment of factors tied to the company’s upcoming earnings report.
24/7 Wall Street compares Johnson & Johnson and Procter & Gamble as Dividend Kings, noting that they trade at nearly identical valuations. It frames the choice around which company can continue raising its payout over the next two decades, citing three factors it says investors often overlook.
Why it matters — The article presents JNJ’s long-term dividend growth as a central consideration alongside its comparison with Procter & Gamble.
The 23 Wall Street analysts covering Johnson & Johnson have a median 12-month price target of $284, with estimates ranging from $190 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Johnson & Johnson, 16 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Johnson & Johnson 85 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Johnson & Johnson ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies +11.3% from the last close, and Ticker Nerd's factor model ranks Johnson & Johnson 85 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Johnson & Johnson publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JNJ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $190 to $320 over the next 12 months.
Johnson & Johnson returned +38.4% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?". A report asks whether J&J’s MedTech business can rebound in Q3 after a Q2 slowdown, noting Abiomed and competitive pressures alongside potential contributions from Vision, Orthopedics and Surgery.
Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care. The company serves hospitals, clinicians, patients, and healthcare systems in markets around the world, making it a central participant in both drug development and medical device supply chains. Johnson & Johnson is known for operating at the intersection of large-scale research, clinical innovation, and essential healthcare delivery, with products that support prevention, treatment, diagnosis, and recovery across a wide range of medical settings.
CEO Mr. Joaquin Duato · 138,200 employees · United States · https://www.jnj.com
